targeted BioGene therapeutics

EpigenoMax Therapeutics is developing an integrated precision oncology platform that combines molecular diagnostics with programmable BioGene therapeutics. The company aims to overcome treatment resistance and improve outcomes for patients with difficult-to-treat cancers by selectively targeting malignant cells while minimizing effects on healthy tissue. Its molecular diagnostic technologies are designed to detect cancers at the molecular level to personalize therapy and guide treatment decisions.

Read more

molecular diagnosticsprecision oncology research